Sector: Financials | Industry: Closed End Funds |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Corporate Center RYE NY 10580-1422 |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
Mario J. Gabelli Chairman of the Board of Trustees, Chief Investment Officer | John C. Ball President, Principal Financial and Accounting Officer, Treasurer | Richard J. Walz Chief Compliance Officer |
Peter D. Goldstein Vice President, Secretary | David I. Schachter Vice President | Adam E. Tokar Vice President | Bethany A. Uhlein Vice President, Ombudsman |
Business Overview |
The Gabelli Healthcare & WellnessRx Trust (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is long term growth of capital. It is focused on investing approximately 80% of its assets in equity securities and income producing securities of domestic and foreign companies in the healthcare and wellness industries. The Fund invests in various geographic regions, including North America, Europe, Japan and Asia/Pacific. The Fund's portfolio of investments in various sectors include food; healthcare providers and services; pharmaceuticals; healthcare equipment and supplies; beverages; biotechnology; household and personal products; electronics; specialty chemicals, and food and staples retailing. Gabelli Funds, LLC serves as the investment advisor of the Fund. |
Financial Overview |
For the fiscal year ended 31 December 2023, Gabelli Healthcare & WellnessRx Trust revenues decreased 2% to $4M. Net income totaled $423K vs. loss of $47.4M. Revenues reflect Dividend- Investment income decrease of 7% to $3.3M. Net Income reflects Unrealized Capital Gains/Losses - Total decrease of 84% to $9.1M (expense), Net realized gain on investments increase of 1% to $11.7M (income). |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $203.26M as of Dec 31, 2023 |
Annual revenue (TTM): | $3.98M as of Dec 31, 2023 |
EBITDA (TTM): | -$2.15M as of Dec 31, 2023 |
Net annual income (TTM): | $0.42M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3.33M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $53.32M as of Dec 31, 2023 |
Shares outstanding: | 16,679,968 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |